Atara Biotherapeutics Company Profile (NASDAQ:ATRA)

Analyst Ratings

Consensus Ratings for Atara Biotherapeutics (NASDAQ:ATRA) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $29.50 (22.92% upside)

Analysts' Ratings History for Atara Biotherapeutics (NASDAQ:ATRA)
Show:
DateFirmActionRatingPrice TargetActions
7/9/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2016Jefferies GroupReiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$40.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$30.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$16.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2014 forward)

Earnings

Earnings History for Atara Biotherapeutics (NASDAQ:ATRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015($0.53)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.44)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015($0.35)($0.67)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($4.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Atara Biotherapeutics (NASDAQ:ATRA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.68)($0.68)($0.68)
Q2 20161($0.65)($0.65)($0.65)
Q3 20161($0.76)($0.76)($0.76)
Q4 20161($0.86)($0.86)($0.86)
Q1 20171($0.87)($0.87)($0.87)
Q2 20171($0.88)($0.88)($0.88)
Q3 20171($0.89)($0.89)($0.89)
Q4 20171($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Atara Biotherapeutics (NASDAQ:ATRA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/21/2016Isaac E CiechanoverCEOSell9,600$22.11$212,256.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2016Isaac E CiechanoverCEOSell9,600$22.88$219,648.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016John McgrathCFOSell5,395$15.77$85,079.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015John McgrathCFOSell6,000$40.00$240,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Atara Biotherapeutics (NASDAQ:ATRA)
DateHeadline
07/28/16 11:23 AMInsider Trading to Watch for: Atara Biotherapeutics Inc (NASDAQ:ATRA) - The Voice Registrar
07/27/16 02:39 PMCan Shares Of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Hit $25? - Investor Newswire
07/26/16 11:41 AMWestinghouse Air Brake Technologies Corporation (NYSE:WAB) plummeted -6.89%: Atara Biotherapeutics (NASDAQ ... - KC Register
07/22/16 07:38 PMInsiders and Institutional Investors Selling, Short Interest Growing Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
07/21/16 02:37 PMEarnings Focus and Crowd Sourced Sentiment Review for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - TGP
07/20/16 10:04 PMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Shorted Shares Increased 12.76% After Market Selling - Consumer Eagle
07/20/16 10:04 PMIs $25 Price Target Attainable For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)? - Investor Newswire
07/19/16 02:38 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 07:33 AMTrading Performance and Target Watch for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Press Telegraph
07/18/16 07:33 AMStock in Positive Territory for the Quarter: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Engelwood Daily
07/17/16 07:22 AMWere Analysts Bearish Atara Biotherapeutics Inc (NASDAQ:ATRA) This Week? - Consumer Eagle
07/16/16 02:36 PMShares Experiencing a Downtrend: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - TGP
07/16/16 02:36 PMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Short Interest Increased By 1.69% - Consumer Eagle
07/14/16 02:41 PMEye on Stock Volatility for: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Engelwood Daily
07/14/16 02:41 PMEye on Stock Volatility for: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Engelwood Daily
07/13/16 10:45 AMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Shorted Shares Increased 1.69% After Market Selling - Consumer Eagle
07/13/16 10:45 AMAtara Biotherapeutics (NASDAQ:ATRA) Sentiment Improved in Q1 2016 - Consumer Eagle
07/13/16 10:45 AMStrong Sell Calls For Atara Biotherapeutics, Inc. (NASDAQ:ATRA) At 0 - Investor Newswire
07/12/16 02:43 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 07:23 AMAtara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoproliferative Disorders - [at noodls] - SOUTH SAN FRANCISCO, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
07/12/16 05:37 AMSeth Klarman Buys Stake in Cascadian Therapeutics as Stock Declines
07/11/16 07:41 PMIsaac Ciechanover, Atara Biotherapeutics Inc (NASDAQ:ATRA)'s insider Sold 9600 Shares - Consumer Eagle
07/10/16 02:35 PMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Sellers Increased By 1.69% Their Shorts - Press Telegraph
07/10/16 07:24 AMNext Weeks Broker Price Targets For Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Fiscal Standard
07/07/16 02:40 PMAtara Biotherapeutics, Inc. Stock Momentum at Critical Inflection Point - CML News
07/07/16 10:33 AMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Updated Price Targets - FTSE News
07/06/16 08:24 PMInsiders are Gradually Selling Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Telanagana Press
07/06/16 07:26 AMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Reach Highs Of $25 - Investor Newswire
07/04/16 02:37 PMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Short Interest Increased By 1.69% - Engelwood Daily
07/02/16 10:19 AMAre Analysts Bearish Atara Biotherapeutics Inc (NASDAQ:ATRA) After Last Week? - Press Telegraph
06/29/16 02:37 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Current Analyst Ratings - Fiscal Standard
06/28/16 02:52 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Earnings Glance and Target Price Review - Engelwood Daily
06/26/16 07:48 AMAtara Biotherapeutics Incorporated (NASDAQ:ATRA) Shorted Shares Increased 1.69% After Market Selling - Press Telegraph
06/25/16 02:38 PMWere Analysts Bullish Atara Biotherapeutics Inc (NASDAQ:ATRA) This Week? - Engelwood Daily
06/25/16 07:19 AMShare Volatility Check for: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Press Telegraph
06/24/16 03:32 PMATARA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/23/16 10:02 PMATARA Biotherapeutics (ATRA) Announces Medicinal Product Classification for Allogeneic EBV-CTLs from EMA
06/23/16 04:06 PMATARA Biotherapeutics (ATRA) Announces Medicinal Product Classification for Allogeneic EBV-CTLs from EMA - StreetInsider.com
06/23/16 08:49 AMAtara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
06/22/16 07:48 PMWith incubator partnership, one of world's largest biotech cozies up to startups
06/22/16 07:26 AMStrong Buy Calls Count For Atara Biotherapeutics, Inc. (NASDAQ:ATRA) At 4 - Investor Newswire
06/19/16 02:36 PMAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 02:40 PMAtara Biotherapeutics : Bio to Present at the JMP Securities Life Sciences Conference
06/16/16 07:01 AMAtara Biotherapeutics, Inc. (ATRA) - Financial and Strategic SWOT Analysis Review - New Market Study Published
06/15/16 03:19 PMAtara Bio to Present at the JMP Securities Life Sciences Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 15, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...
06/13/16 02:54 PMStock Highlights: Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Weatherford International plc (NYSE:WFT), Stein Mart ... - KC Register
06/08/16 08:58 PMATARA BIOTHERAPEUTICS INC. (NASDAQ:ATRA) Financial Condition Compared to S&P 500 - CML News
06/06/16 08:04 PMResults Presented at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
06/06/16 08:04 PMAtara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using
06/06/16 05:48 PMAtara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe ...

Social

About Atara Biotherapeutics

Atara Biotherapeutics logoAtara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ATRA
  • CUSIP:
Key Metrics:
  • Previous Close: $24.05
  • 50 Day Moving Average: $21.94
  • 200 Day Moving Average: $19.01
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $689.86M
  • Beta: 0.71
  • Current Year EPS Consensus Estimate: $-2.6 EPS
  • Next Year EPS Consensus Estimate: $-3 EPS
Additional Links:
Atara Biotherapeutics (NASDAQ:ATRA) Chart for Sunday, July, 31, 2016